Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARF6 | P62330 | 10/20 | 0.55 |
| ▸ | PSD | A5PKW4 | 5/20 | 0.52 |
| ▸ | SLC27A2 | O14975 | 1/20 | 0.43 |
| ▸ | CDC7 | O00311 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13516218 | 0.92 | ARF6 (0.65) | ARF6PSDSLC27A2 | |
| SCHEMBL19084585 | 0.89 | PSD (0.55) | ARF6PSDSLC27A2MAPTMCL1 | |
| SCHEMBL19084683 | 0.88 | PSD (0.55) | ARF6PSDSLC27A2POLBMAPT | |
| SCHEMBL14899468 | 0.85 | ARF6 (0.56) | ARF6PSDSLC27A2MAPTMEN1 | |
| SCHEMBL19084617 | 0.85 | ARF6 (0.50) | ARF6PSDSLC27A2POLBMAPT | |
| SCHEMBL19084591 | 0.83 | ARF6 (0.54) | ARF6PSDSLC27A2 | |
| SCHEMBL19084680 | 0.81 | ARF6 (0.76) | ARF6PSDSLC27A2 | |
| SCHEMBL13516748 | 0.81 | ARF6 (0.60) | ARF6PSD | |
| SCHEMBL13516359 | 0.80 | PSD (0.48) | ARF6PSDSLC27A2POLBMAPT | |
| SCHEMBL19084611 | 0.80 | PSD (0.56) | ARF6PSDPOLBMAPTMCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10849901-B2 | Arf6 inhibitors and methods of synthesis and use thereof | NAVIGEN, INC. (US) | 2020-12-01 | — | — | US | disclosed |
| US-20170189405-A1 | ARF6 INHIBITORS AND METHODS OF SYNTHESIS AND USE THEREOF | NAVIGEN, INC. (US) | 2017-07-06 | — | — | US | disclosed |
| US-20170189405-A1 | ARF6 INHIBITORS AND METHODS OF SYNTHESIS AND USE THEREOF | NAVIGEN, INC. (US) | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170189405-A1 | ARF6 INHIBITORS AND METHODS OF SYNTHESIS AND USE THEREOF | ARF6, ARF1, ARFIP2 | ARF6 1/4885PSD 211/4885SLC27A2 2424/4885 |
| US-10849901-B2 | Arf6 inhibitors and methods of synthesis and use thereof | ARF6, ARF1, ARFIP2 | ARF6 1/4885PSD 211/4885SLC27A2 2424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.